of an initial 81 patients undergoing major cardiac surgery (both coronary artery bypass and valve repair procedures) at our teaching hospital, 67 patients were selected for this study. Patients receiving significant intraoperative transfusion and or K-centra were excluded. In the first study, we selected patients who received no blood product and compared estimated blood loss, decrease in percent hemoglobin and hematocrit following surgery between two groups of patients, one group receiving no tranexamic acid (n = 17) and another group receiving tranexamic acid (n = 25). In the second study, we combined these patients with patients receiving modest amounts of blood products (1-2 units) and compared these parameters between two groups of patients (25 patients received no tranexamic acid, 42 patients received tranexamic acid). Statistical analyses were performed using independent t-test, two-tailed, and a difference was considered statistically significant at 95% confidence interval or higher (P ≤ .05). In patients who received no blood products during surgery, those who received no tranexamic acid showed statistically significant reduced estimated blood loss (mean: 713.5 mL, SD: 351.6, n = 17) compared to those who received tranexamic acid (mean 987.2 mL, SD 459.9, n = 25). However, no statistically significant difference was observed in percent reduced hemoglobin concentration or percent reduced hematocrit associated with surgery between these two groups of patients. We observed similar results when patients receiving no blood products and patients receiving modest amount of blood products were combined based on use of tranexamic acid or not, as only estimated blood loss between these two groups was statistically significant (estimated blood loss in patients not receiving tranexamic acid: mean 814.0 mL, SD 501.6, n = 25; and estimated blood loss in patients receiving tranexamic acid: mean 1,207.1 mL, SD 488.6, n = 42). We conclude that intraoperative antifibrinolytic therapy with tranexamic acid does not reduce intraoperative blood loss during major cardiac surgery, which contradicts popular belief. Objective: Red blood cell (RBC) exchange remains an effective therapy for acute sickle cell disease. Two main factors play into the decision: clinical presentation and hemoglobin S (HgS) concentration. Patients with severe acute complications may benefit from emergent RBC exchange. Knowing the patient's HgS level will facilitate the clinical decision and limit unnecessary exposure to blood products and invasive procedures. Conventional quantitative laboratory methods, eg, capillary electrophoresis, may have turnaround times unsuitable for acute management. The sickling hemoglobin solubility test is a rapid but qualitative measurement of HgS commonly used in blood banks. We developed a variation of the solubility test with serial dilution to provide a rapid semiquantitative estimate of HgS concentration. Method: Packed RBC samples with a wide range of HgS concentrations were obtained from 18 individuals for whom hemoglobin analysis by capillary electrophoresis was ordered. Each of the samples was mixed with nonHgS control RBCs at different patient:control ratios (10:0 uL; 6.6:3.3 uL; 5:5 uL; 3.3:6.6 uL), and 10 µL of the mixture was added to 2.0 mL of a commercial solubility test buffer (Streck, Omaha, NE). Each tube was visually evaluated for turbidity and compared to two controls that had 15% HgS (undetectable turbidity) and 20% HgS (detectable turbidity). Based on the highest dilution with detectable turbidity, each sample was given an estimate of HgS concentration: "<20%," "15% to 30%," "22.5% to 40%," "30% to 60%," and ">45%." Results: Of the 18 cases, all except one estimate obtained by the modified solubility test was consistent with the HgS concentration obtained by capillary electrophoresis. The one discrepant sample had 42.3% HgS, 2.3% higher than the estimated value range 22.5% to 40%. Conclusion: Via a serial dilution approach, we can rapidly evaluate the HgS level of patients being considered for RBC exchange using a solubility test in minutes. Although the current technique can only provide a semiquantitative estimate, the findings still provide meaningful support for clinical decision-making in the treatment of acute sickle cell disease. This technique may also be useful in resourcepoor countries to quickly distinguish homozygous HgS from heterozygous HgS conditions in patients with sickle cell disease.
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Utility of Epinephrine in Determining Accurate Catheterization in Adrenal Vein Sampling Procedures
Luis Carrillo, Dawn Monzel, Pratistha Ranjitkar, Jessica Colon-Franco; Medical College of Wisconsin, Milwaukee
Background: Primary aldosteronism (PA) is the most common cause of secondary hypertension resulting from autonomous production of aldosterone by the adrenal glands. PA subtype classification through adrenal vein sampling (AVS) is important to differentiate the major subtypes of PA (aldosterone-producing adenoma [APA], unilateral adrenal hyperplasia, and idiopathic bilateral adrenal hyperplasia). APA is surgically curable, while the others are treated medically. AVS consists of directly sampling the adrenal vein (AV) effluent and comparing aldosterone levels bilaterally. Accurate AV catheterization is crucial for a correct diagnosis and is verified by comparing the concentration of cortisol in the AV effluent and the inferior vena cava (IVC). A cortisol-AV/cortisol-IVC ratio or selectivity index (SI) >3-4 typically indicates successful cannulation. However, cortisol is not always reliable, and alternative measurements such as metanephrine or epinephrine have been suggested. In addition to cortisol, our institution measures epinephrine with the rationale that AV epinephrine is significantly higher than peripheral levels. However, limited data demonstrate the utility of epinephrine in AVS catheterization. Here, we derived the SI for epinephrine and examined whether measuring epinephrine adds value in determining AV selectivity. Methods: We investigated 105 consecutive AVS procedures performed at our institution between June 14, 2011 and February 7, 2017 in 104 patients (64 men, 40 women, average age 54.1 years). All procedures used cosyntropin stimulation. Cortisol, aldosterone, and epinephrine were measured in all collections, typically, one IVC, one left AV (LAV), and up to three right AV (RAV; RAV2, n = 50; RAV3, n = 2). Successful AV catheterization was determined using a cortisol SI >4. The optimal epinephrine SI was derived from the RAV1 results and receiver-operating characteristics (ROC) curve analysis (control, n = 17; catheterized, n = 88). Using the derived SI, catheterization was assessed in the RAV2-3 subsets. Results: LAV and RAV catheterization was successful in 96% and 84% of procedures, respectively. One case with failed initial RAV sampling had successful catheterization in a subsequent sampling attempt, for an overall RAV cannulation success rate of 85%. The area under the curve for epinephrine and selectivity was 0.90 (95% confidence interval [CI]: 0.83-0.98, P < .0001). The optimal epinephrine SI was >25 (94% sensitivity, CI: 87-98; 82% specificity, CI: 57-96). When applied to other AVS subsets, this SI indicated catheterization in two of 13 RAV2 and one of four LAV collections deemed unsuccessful using cortisol selectivity criteria. This represents 4% of RAV2 and 1% of LAV collections. Conclusion: Measuring epinephrine for AVS selectivity added value in a small number of AVS cases for which cortisol criteria failed to predict catheterization. Consideration should be given to limiting its use to complicated cases (e.g. complex RAV anatomy). Cost-benefit analysis of measuring epinephrine for AVS and studying the broad applicability of the epinephrine SI is warranted.
